colleagues. They found that patients who received ICIs had lower overall survival rates compared to those in clinical trials. The study included a diverse group of nearly 12,000 cancer patients from the Veterans Affairs system. These findings suggest that the real-world response to ICIs may not be as positive as initially thought based on trial data. Further research is needed to understand and address potential disparities in outcomes between clinical trials and real-world settings when it comes to the use of immune checkpoint inhibitors.
Source link
Outcomes Less Than Expected in Largest Real-World Study of ICIs
